Navigation Links
BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
Date:5/7/2012

LYNBROOK, N.Y., May 7, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, announced today a rescheduled date and time for its conference call and live audio webcast to report its first quarter 2012 financial results and provide a corporate update. The conference call is now scheduled for 4:30 p.m. EDT on Thursday, May 10, 2012. The Company will issue a financial results press release earlier that afternoon.

In order to participate in the conference call, please dial 1-800-860-2442 (domestic) or 1-412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.videonewswire.com/event.asp?id=86553.

A replay of the call will be available one hour after the end of the conference on May 10, 2012 until 9:00 a.m. EDT on May 23, 2012. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10013068. The archived webcast will be available for 90 days in the Investor Relations section of BioSpecifics' website at www.biospecifics.com.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Today, injectable collagenase, registered as XIAFLEX®, is marketed in the U.S. for the treatment of Dupuytren's contracture in adults with a palpable cord by the Company's partner Auxilium Pharmaceuticals, Inc. (Auxilium) and is marketed in Europe under the trademark XIAPEX® by Pfizer Ltd. (Pfizer). XIAFLEX will be tested in the clinic for six promising indications during 2012: Auxilium is developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase III pivotal clinical trials, as well as for frozen shoulder (adhesive capsulitis) and cellulite, which are in Phase II and Phase I, respectively. Auxilium is also conducting a Phase IIIb trial of XIAFLEX for Dupuytren's contracture patients with multiple palpable cords. BioSpecifics is developing XIAFLEX for human and canine lipomas. Pfizer has development and commercialization rights for XIAPEX for Dupuytren's contracture and Peyronie's disease in the 27 European Union member countries and 19 other European and Eurasian countries. Asahi Kasei Pharma Corporation has development and commercialization rights for XIAFLEX for the same two indications in Japan, and Actelion Pharmaceuticals has development and commercialization rights for XIAFLEX for these two indications in Canada, Australia, Brazil and Mexico. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
2. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
4. BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results
5. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
6. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
7. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
8. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
9. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
10. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
11. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... 2019 , ... Doral Health & Wellness, a multispecialty, interdisciplinary ... Center on Pitkin Avenue in the Brownsville section of Brooklyn. , The beautifully ... diabetes. Seniors can take part in fitness and meditation classes, art and music ...
(Date:11/6/2019)... ... November 06, 2019 , ... Dutch Bros Coffee raised $333,360 for ... Month. $10 from each “Be Aware” mug sold in October was donated to patient ... opportunity to help support these amazing organizations,” said Travis Boersma, CEO and co-founder of ...
(Date:11/6/2019)... ... 2019 , ... Regen Suppliers is now offering a first ... all others on the market including extremely high particle counts, and Regen Suppliers ... more information and ordering. , As a comprehensive distributor of regenerative products and ...
Breaking Medicine Technology:
(Date:11/9/2019)... (PRWEB) , ... November 08, 2019 , ... The Women’s ... President-Elect due to health concerns. The WDS Board of Directors appointed Molly Hinshaw, MD ... will complete the current March 2019-March 2020 term and will be presented to the ...
(Date:11/7/2019)... HAUPPAUGE, N.Y. (PRWEB) , ... November 06, 2019 , ... ... in fighting the flu is to get the flu shot. Since the flu season ... Flu Vaccination Clinic in early Fall, where their employees can simply sign-up and get ...
(Date:11/7/2019)... Va. (PRWEB) , ... November 07, 2019 , ... Understanding ... – 3:00 p.m. EST, https://www.fdanews.com/understandudi , Are EU device and IV diagnostics ... to new EU device regulations —UDI — is ahead, and many device and diagnostics ...
(Date:11/6/2019)... , ... November 06, 2019 , ... ... in the health plan market, announced today that 94% of the health insurance ... private, Medicare, and Medicaid health insurance plans, use SPH solutions according to ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... Innovative Techniques , to Improve Inspections, An FDAnews Workshop, Nov. 13-14, 2019 • ... Investigations starts in one week. , Dear FDA-Regulated Executive, , CAPA failures show ...
Breaking Medicine News(10 mins):